July 16, 2015
Dr Taniguchi (left), Dr Shin Armed with the anti-PD-L1 antibody MEDI4736, AstraZeneca (AZ) is exploring the potential of immunotherapies with an array of other pipeline compounds inside the company. In the third of this series, we talked with two officials...read more